ArticlePLoS pathogens2010
Origin and evolution of sulfadoxine resistant Plasmodium falciparum.
Article in PLoS pathogens, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 133 citations in OpenAlex.
- Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment.Antimicrobial agents and chemotherapy · 2015Trial
- A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India.Malaria journal · 2013Trial
- Digital Health Center App for Community and National Malaria Surveillance in Cambodia: Implementation Case Study.JMIR public health and surveillance · 2026Article
- A spatio-temporal model of multi-marker antimalarial resistance.Journal of the Royal Society, Interface · 2024Article
- Geographical emergence of sulfadoxine-pyrimethamine drug resistance-associatedAntimicrobial agents and chemotherapy · 2023Article
- Polymorphism of Drug Resistance GenesTropical medicine and infectious disease · 2023Article
- Allelic frequencies of mutants of theHeliyon · 2022Article
- Molecular surveillance for anti-malarial drug resistance and genetic diversity of Plasmodium falciparum after chloroquine and sulfadoxine-pyrimethamine withdrawal in Quibdo, Colombia, 2018.Malaria journal · 2022Article
- Article
- Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa.Malaria journal · 2021Article
- Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.The Lancet. Infectious diseases · 2021Article
- Surveillance of Antimalarial Drug-Resistance Genes in ImportedFrontiers in cellular and infection microbiology · 2021Article
- Changes in the frequencies of Plasmodium falciparum dhps and dhfr drug-resistant mutations in children from Western Kenya from 2005 to 2018: the rise of Pfdhps S436H.Malaria journal · 2020Article
- Article
- Molecular and epidemiological characterization of imported malaria cases in Chile.Malaria journal · 2020Article
- Population genomics identifies a distinct Plasmodium vivax population on the China-Myanmar border of Southeast Asia.PLoS neglected tropical diseases · 2020Article
- High multiple mutations of Plasmodium falciparum-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria.Infectious diseases of poverty · 2020Article
- Local emergence in Amazonia ofeLife · 2020Article
- Artemether-Lumefantrine Efficacy for the Treatment of UncomplicatedThe American journal of tropical medicine and hygiene · 2020Article
- Molecular characterization of Plasmodium falciparum antifolate resistance markers in Thailand between 2008 and 2016.Malaria journal · 2020Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 3 countries.
Funding
Abstract
The Thailand-Cambodia border is the epicenter for drug-resistant falciparum malaria. Previous studies have shown that chloroquine (CQ) and pyrimethamine resistance originated in this region and eventually spread to other Asian countries and Africa. However, there is a dearth in understanding the origin and evolution of dhps alleles associated with sulfadoxine resistance. The present study was designed to reveal the origin(s) of sulfadoxine resistance in Cambodia and its evolutionary relationship to African and South American dhps alleles. We sequenced 234 Cambodian Plasmodium falciparum isolates for the dhps codons S436A/F, A437G, K540E, A581G and A613S/T implicated in sulfadoxine resistance. We also genotyped 10 microsatellite loci around dhps to determine the genetic backgrounds of various alleles and compared them with the backgrounds of alleles prevalent in Africa and South America. In addition to previously known highly-resistant triple mutant dhps alleles SGEGA and AGEAA (codons 436, 437, 540, 581, 613 are sequentially indicated), a large proportion of the isolates (19.3%) contained a 540N mutation in association with 437G/581G yielding a previously unreported triple mutant allele, SGNGA. Microsatellite data strongly suggest the strength of selection was greater on triple mutant dhps alleles followed by the double and single mutants. We provide evidence for at least three independent origins for the double mutants, one each for the SGKGA, AGKAA and SGEAA alleles. Our data suggest that the triple mutant allele SGEGA and the novel allele SGNGA have common origin on the SGKGA background, whereas the AGEAA triple mutant was derived from AGKAA on multiple, albeit limited, genetic backgrounds. The SGEAA did not share haplotypes with any of the triple mutants. Comparative analysis of the microsatellite haplotypes flanking dhps alleles from Cambodia, Kenya, Cameroon and Venezuela revealed an independent origin of sulfadoxine resistant alleles in each of these regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.